The Society of Surgical Oncology, inc.
The American Society of Breast Surgeons.
Annals of Surgical Oncology

Log in | Register

Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma

Michael S. Sabel MD, Jay Lee BS, Shijie Cai PhD, Michael J. Englesbe MD, Stephen Holcombe MS, Stewart Wang MD, PhD
Melanomas
Volume 18, Issue 13 / December , 2011

Abstract

Background

Several hypotheses proposed to explain the worse prognosis for older melanoma patients include different tumor biology and diminished host response. If the latter were true, then biologic frailty, and not age, should be an independent prognostic factor in melanoma.

Methods

Our prospective institutional review board (IRB)-approved database was queried for stage III patients with computed tomography (CT) scans at time of lymph node dissection (LND). Psoas area (PA) and density (PD) were determined in semi-automated fashion. Kaplan–Meier (K–M) survival estimates and Cox proportional-hazard models were used to determine PA and PD impact on survival and surgical complications.

Results

Among 101 stage III patients, PD was significantly associated with both disease-free survival (DFS) (P = 0.04) and distant disease-free survival (DDFS) (P = 0.0002). Cox multivariate modeling incorporating thickness, age, ulceration, and N stage showed highly significant association with PD and both DFS and DDFS. DDFS was significantly associated with Breslow thickness (P = 0.04), number of positive nodes (P = 0.001), ulceration (P = 0.04), and decreasing muscle density (P = 0.01), with hazard ratio of 0.55 [95% confidence interval (CI) 0.35–0.87]. PD also correlated with surgical complications, with odds ratio (OR) of 1.081 [95% CI 1.016–1.150, P = 0.01].

Conclusions

Decreased psoas muscle density on CT, an objective measure of frailty, was as important a predictor of outcome as tumor factors in a cohort of stage III melanoma patients. On multivariate analysis, frailty, not age, was associated with decreased disease-free survival and distant disease-free survival, and higher rate of surgical complications.

Add a comment



0 comment(s)

ANNALS NOW ON TWITTER!

@AnnSurgOncol

Follow the journal on Twitter and help to expand the reach of the journal to help surgical oncologists and their patients.

 

MANUSCRIPT PROCESSING FEE

Effective January 2013, a manuscript processing fee of $50 USD is required for each initial new submission of an Annals article, excluding editorials. Submitted new manuscripts will not enter the review process until the submission fee has been paid. There is no processing fee associated with resubmitted manuscripts.

 

HIGHLIGHTED VIDEO OF THE MONTH

Lymphatic Mapping and Sentinel Node Biopsy in the Colonic Mesentery by Natural Orifice Transluminal Endoscopic Surgery (NOTES) by R. A. Cahill MD, FRCS, S. Perretta MD, J. Leroy MD, B. Dallemagne MD, and J. Marescaux MD, FRCS, FACS.  Annals of Surgical Oncology. Volume 15, Number 10, DOI: 10.1245/s10434-008-9952-8